Rho kinase inhibitors ameliorate cognitive impairment in a male mouse model of methamphetamine-induced schizophrenia

Keyphrases

• Schizophrenia 100%
• Cognitive Impairment 100%
• Methamphetamine 100%
• Mouse Model 100%
• Rho Kinase Inhibitor 100%
• Male Mice 100%
• Dorsolateral Striatum 40%
• Prelimbic Cortex 40%
• Fasudil 40%
• Rho Kinase 30%
• Visual Discrimination 30%
• Clozapine 20%
• Haloperidol 20%
• Negative Symptoms 20%
• Positive Symptoms 20%
• Oral Administration 20%
• Cognitive Deficits 10%
• Phosphorylation 10%
• Microinjection 10%
• Myosin Phosphatase Target Subunit 1 10%
• Y-27632 10%
• Hyperactivity 10%
• Schizophrenia Models 10%
• Neurite Extension 10%
• Systemic Injection 10%
• Small GTPase 10%
• Visual Discrimination Task 10%
• Severe Mental Illness 10%
• Pathoaetiology 10%
• Myosin Light Chain Kinase 10%
• Rho Kinase Inhibitor Fasudil 10%
• Neuronal Architecture 10%
• Corticostriatal Circuits 10%
• Antipsychotic Treatment 10%
• Small GTPase Signaling 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Cognitive Defect 100%
• Mouse Model 100%
• Rho Kinase Inhibitor 100%
• Schizophrenia 100%
• Fasudil 83%
• Rho Kinase 50%
• 4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol 33%
• Positive Syndrome 33%
• Negative Syndrome 33%
• Clozapine 33%
• Oral Administration 33%
• Antipsychotic 16%
• Hyperactivity 16%
• Guanosine Triphosphatase 16%
• Myosin Light Chain Kinase 16%
• Rho Guanine Nucleotide Binding Protein 16%
• Myosin 16%
• Side Effect 16%
• Phosphatase 16%
• Mental Diseases 16%